Immunologic minimal residual disease detection in acute lymphoblastic leukemia: A comparative approach to molecular testing

Best Practice and Research: Clinical Haematology

Volumn 23, Issue 3, 2010, Pages 347-358

  Coustan Smith, Elaine ^a   Campana, Dario ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Acute lymphoblastic leukemia; Flow cytometry; Minimal residual disease; Polymerase chain reaction

Indexed keywords

CD103 ANTIGEN; CD11 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD34 ANTIGEN; CD45RA ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; T LYMPHOCYTE RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; B LYMPHOCYTE; CANCER DIAGNOSIS; CELL LINEAGE; DIAGNOSTIC ACCURACY; FLOW CYTOMETRY; GENE AMPLIFICATION; GENE EXPRESSION; GENE REARRANGEMENT; HUMAN; IMMUNOPHENOTYPING; INTERMETHOD COMPARISON; LEUKEMIA CELL; LYMPHOID CELL; MINIMAL RESIDUAL DISEASE; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC TESTS; IMMUNOPHENOTYPING; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 78649506177     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2010.07.007     Document Type: Review

References (86)

1. K.F. Bradstock, G. Janossy, and N. Tidman Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia Leuk Res 5 1981 301 309
2. M.N. Dworzak, G. Froschl, and D. Printz CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease Leukemia 18 2004 703 708
3. D. Campana, and E. Coustan-Smith Detection of minimal residual disease in acute leukemia by flow cytometry Cytometry 38 1999 139 152
4. L.M. Rimsza, R.S. Larson, and S.S. Winter Benign hematogone-rich lymphoid proliferations can be distinguished from B-lineage acute lymphoblastic leukemia by integration of morphology, immunophenotype, adhesion molecule expression, and architectural features Am J Clin Pathol 114 2000 66 75
5. R.W. McKenna, L.T. Washington, and D.B. Aquino Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry Blood 98 2001 2498 2507
6. C.A. Hurwitz, M.R. Loken, and M.L. Graham Asynchronous antigen expression in B lineage acute lymphoblastic leukemia Blood 72 1988 299 307
7. D. Campana, E. Coustan-Smith, and G. Janossy The immunologic detection of minimal residual disease in acute leukemia Blood 76 1990 163 171
8. J. Ciudad, J.F. San Miguel, and M.C. Lopez-Berges Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia J Clin Oncol 16 1998 3774 3781
9. P. Lucio, A. Parreira, and M.W. van den Beemd Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B- ALL Leukemia 13 1999 419 427
10. E. Coustan-Smith, F.G. Behm, and J. Sanchez Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia Lancet 351 1998 550 554
11. N. Farahat, A. Morilla, and K. Owusu-Ankomah Detection of minimal residual disease in B-lineage acute lymphoblastic leukaemia by quantitative flow cytometry Br J Haematol 101 1998 158 164
12. M.N. Dworzak, G. Fritsch, and C. Fleischer Comparative phenotype mapping of normal vs. malignant pediatric B- lymphopoiesis unveils leukemia-associated aberrations Exp Hematol 26 1998 305 313
13. M. De Waele, W. Renmans, and K. Jochmans Different expression of adhesion molecules on CD34+ cells in AML and B-lineage ALL and their normal bone marrow counterparts Eur J Haematol 63 1999 192 201
14. E. Coustan-Smith, J. Sancho, and F.G. Behm Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia Blood 100 2002 52 58
15. T. Muzzafar, L.J. Medeiros, and S.A. Wang Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry Am J Clin Pathol 132 2009 692 698
16. J.A. DiGiuseppe, S.G. Fuller, and M.J. Borowitz Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection Cytometry B Clin Cytom 76 2009 150 155
17. M. Djokic, E. Bjorklund, and E. Blennow Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia Haematologica 94 2009 1016 1019
18. J.S. Chen, E. Coustan-Smith, and T. Suzuki Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia Blood 97 2001 2115 2120
19. M. Veltroni, L. De Zen, and M.C. Sanzari Expression of CD58 in normal, regenerating and leukemic bone marrow B cells: implications for the detection of minimal residual disease in acute lymphocytic leukemia Haematologica 88 2003 1245 1252
20. G. Gaipa, G. Basso, and O. Maglia Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection Leukemia 19 2005 49 56
21. R.V. Lee, R.C. Braylan, and L.M. Rimsza CD58 expression decreases as nonmalignant B cells mature in bone marrow and is frequently overexpressed in adult and pediatric precursor B-cell acute lymphoblastic leukemia Am J Clin Pathol 123 2005 119 124
22. E. Mejstrikova, E. Fronkova, and T. Kalina Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry Pediatr Blood Cancer 54 2010 62 70
23. D.A. Wells, G.E. Sale, and H.M. Shulman Multidimensional flow cytometry of marrow can differentiate leukemic from normal lymphoblasts and myeloblasts after chemotherapy and bone marrow transplantation Am J Clin Pathol 110 1998 84 94
24. E. Coustan-Smith, R.C. Ribeiro, and P. Stow A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome Blood 108 2006 97 102
25. D. Campana Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia Hematol Oncol Clin North Am 23 2009 1083 1098 vii
26. E. Coustan-Smith, J. Sancho, and M.L. Hancock Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia Blood 96 2000 2691 2696
27. M.N. Dworzak, G. Froschl, and D. Printz Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia Blood 99 2002 1952 1958
28. J. Sanchez, J. Serrano, and P. Gomez Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation Br J Haematol 116 2002 686 694
29. E. Coustan-Smith, A. Gajjar, and N. Hijiha Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse Leukemia 18 2004 499 504 (Pubitemid 38425864)
30. M.J. Borowitz, M. Devidas, and S.P. Hunger Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors. A Children's Oncology Group study Blood 111 2008 5477 5485
31. E.A. Raetz, M.J. Borowitz, and M. Devidas Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: a Children's Oncology Group Study J Clin Oncol 26 2008 3971 3978
32. G. Basso, M. Veltroni, and M.G. Valsecchi Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow J Clin Oncol 27 2009 5168 5174
33. J. Motwani, J. Jesson, and E. Sturch Predictive value of flow cytometric minimal residual disease analysis in childhood acute lymphoblastic leukaemia at the end of remission induction therapy: results from a single UK centre Br J Haematol 144 2009 133 135
34. I. Elorza, C. Palacio, and J.L. Dapena Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia Haematologica 95 2010 936 941
35. E. Coustan-Smith, J. Sancho, and M.L. Hancock Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia Blood 100 2002 2399 2402
36. E. Coustan-Smith, J.T. Sandlund, and S.L. Perkins Minimal disseminated disease in childhood T-cell lymphoblastic lymphoma: a report from the Children's Oncology Group J Clin Oncol 27 2009 3533 3539
37. M. Krampera, A. Vitale, and C. Vincenzi Outcome prediction by immunophenotypic minimal residual disease detection in adult T-cell acute lymphoblastic leukaemia Br J Haematol 120 2003 74 79
38. M.B. Vidriales, J.J. Perez, and C. Lopez-Berges Minimal residual disease (MRD) in adolescent (>14 years) and adult acute lymphoblastic leukaemias (ALL): early immunophenotypical evaluation has high clinical value Blood 101 2003 4695 4700
39. J. Holowiecki, M. Krawczyk-Kulis, and S. Giebel Status of minimal residual disease after induction predicts outcome in both standard and high-risk Ph-negative adult acute lymphoblastic leukaemia. The Polish Adult Leukemia Group ALL 4-2002 MRD Study Br J Haematol 19 2008
40. M. Krampera, O. Perbellini, and C. Vincenzi Methodological approach to minimal residual disease detection by flow cytometry in adult B-lineage acute lymphoblastic leukemia Haematologica 91 2006 1109 1112
41. M. Bruggemann, A. Schrauder, and T. Raff Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008 Leukemia 24 2010 521 535
42. V. van der Velden, A. Hochhaus, and G. Cazzaniga Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects Leukemia 17 2003 1013 1034
43. M.J. Brisco, J. Condon, and E. Hughes Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction Lancet 343 1994 196 200
44. H. Cave, J. van der Werff ten Bosch, and S. Suciu Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer-Childhood Leukemia Cooperative Group N Engl J Med 339 1998 591 598
45. J.J. van Dongen, T. Seriu, and E.R. Panzer-Grumayer Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood Lancet 352 1998 1731 1738 (Pubitemid 28534955)
46. E.R. Panzer-Grumayer, M. Schneider, and S. Panzer Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia Blood 95 2000 790 794
47. A. Biondi, M.G. Valsecchi, and T. Seriu Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group Leukemia 14 2000 1939 1943
48. C. Eckert, A. Biondi, and K. Seeger Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia Lancet 358 2001 1239 1241 (Pubitemid 33010852)
49. J. Zhou, M.A. Goldwasser, and A. Li Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01 Blood 110 2007 1607 1611
50. N. Hagedorn, C. Acquaviva, and E. Fronkova Submicroscopic bone marrow involvement in isolated extramedullary relapses in childhood acute lymphoblastic leukemia: a more precise definition of "isolated" and its possible clinical implications, a collaborative study of the Resistant Disease Committee of the International BFM study group Blood 110 2007 4022 4029
51. M. Paganin, M. Zecca, and G. Fabbri Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia Leukemia 22 2008 2193 2200
52. T. Flohr, A. Schrauder, and G. Cazzaniga Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia Leukemia 22 2008 771 782
53. A. Attarbaschi, G. Mann, and R. Panzer-Grumayer Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials J Clin Oncol 26 2008 3046 3050
54. V. van der Velden, L. Corral, and M.G. Valsecchi Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol Leukemia 23 2009 1073 1079
55. P. Bader, H. Kreyenberg, and G.H. Henze Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group J Clin Oncol 27 2009 377 384
56. R. Sutton, N.C. Venn, and J. Tolisano Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia Br J Haematol 146 2009 292 299
57. V. Conter, C.R. Bartram, and M.G. Valsecchi Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study Blood 115 2010 3206 3214
58. P. Stow, L. Key, and X. Chen Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia Blood 115 2010 4657 4663
59. B. Wassmann, H. Pfeifer, and M. Stadler Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) Blood 106 2005 458 463
60. F. Pane, G. Cimino, and B. Izzo Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia Leukemia 19 2005 628 635
61. M. Bruggemann, T. Raff, and T. Flohr Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia Blood 107 2006 1116 1123
62. T. Raff, N. Gokbuget, and S. Luschen Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials Blood 109 2007 910 915
63. O. Spinelli, B. Peruta, and M. Tosi Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia Haematologica 92 2007 612 618
64. R. Bassan, O. Spinelli, and E. Oldani Improved risk classification for risk-specific therapy based on the molecular study of MRD in adult ALL Blood 113 2009 4153 4162
65. B. Patel, L. Rai, and G. Buck Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993 Br J Haematol 148 2010 80 89
66. M. Yanada, I. Sugiura, and J. Takeuchi Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy Br J Haematol 143 2008 503 510
67. S. Giebel, B. Stella-Holowiecka, and M. Krawczyk-Kulis Status of minimal residual disease determines outcome of autologous hematopoietic SCT in adult ALL Bone Marrow Transplant 45 2010 1095 1101
68. G.A. Neale, E. Coustan-Smith, and P. Stow Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia Leukemia 18 2004 934 938
69. G. Kerst, H. Kreyenberg, and C. Roth Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR Br J Haematol 128 2005 774 782
70. J. Irving, J. Jesson, and P. Virgo Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting Haematologica 94 2009 870 874
71. V. van der Velden, G. Cazzaniga, and A. Schrauder Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data Leukemia 21 2007 604 611
72. M.N. Dworzak, G. Gaipa, and A. Schumich Modulation of antigen expression in B-cell precursor acute lymphoblastic leukemia during induction therapy is partly transient: evidence for a drug-induced regulatory phenomenon. Results of the AIEOP-BFM-ALL-FLOW-MRD-Study Group Cytometry B Clin Cytom 78 2010 147 153
73. T. Szczepanski, M.J. Willemse, and B. Brinkhof Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease Blood 99 2002 2315 2323
74. V. van der Velden, M. Bruggemann, and P.G. Hoogeveen TCRB gene rearrangements in childhood and adult precursor-B-ALL: frequency, applicability as MRD-PCR target, and stability between diagnosis and relapse Leukemia 18 2004 1971 1980
75. J. Gabert, E. Beillard, and V. van der Velden Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program Leukemia 17 2003 2318 2357
76. C.H. Pui, D. Campana, and D. Pei Treating childhood acute lymphoblastic leukemia without cranial irradiation N Engl J Med 360 2009 2730 2741
77. K.R. Schultz, D.J. Pullen, and H.N. Sather Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG) Blood 109 2007 926 935
78. D. Campana Molecular determinants of treatment response in acute lymphoblastic leukemia Hematology Am Soc Hematol Educ Program 2008 366 373
79. C.G. Mullighan, X. Su, and J. Zhang Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia N Engl J Med 360 2009 470 480
80. E. Coustan-Smith, C.G. Mullighan, and M. Onciu Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia Lancet Oncol 10 2009 147 156
81. G. Cario, M. Stanulla, and B.M. Fine Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia Blood 105 2005 821 826
82. C. Flotho, E. Coustan-Smith, and D. Pei Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2 Blood 108 2006 1050 1057
83. C. Flotho, E. Coustan-Smith, and D. Pei A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia Blood 110 2007 1271 1277
84. J.J. Yang, C. Cheng, and W. Yang Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia J Am Med Assoc 301 2009 393 403
85. H. Kang, I.M. Chen, and C.S. Wilson Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia Blood 115 2010 1394 1405
86. C. le Viseur, M. Hotfilder, and S. Bomken In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties Cancer Cell 14 2008 47 58